Tag: Sanofi
Sanofi is developing in partnership a French solution for recycling insulin injector pens
By Alexandra Saintpierre Published on 03/21/2024 at 3:14 p.m. Photo credit © Sanofi (Boursier.com) — On the…
Sanofi: Stifel raises its recommendation
(CercleFinance.com) – Stifel raises its recommendation on Sanofi from ‘hold’ to ‘buy’ with a price target raised from 95 to 109 euros, with an adjustment to the value of the…
Stifel goes to Purchase on Sanofi
(AOF) – Stifel goes from Hold to Buy on Sanofi, with a price target raised from 95 to 109 euros. “We are reasonably optimistic about Sanofi’s ability to post a…
Sanofi: new positive results in atopic dermatitis
(CercleFinance.com) – Sanofi reports positive results from part 2 of the phase IIb STREAM-AD study relating to amlitelimab, which support its potential as the best drug in its class in…
Sanofi tops CAC after results against atopic dermatitis
(AOF) – Sanofi (+1.17% to 88.72 euros) occupies first place in the CAC 40 after having published new phase II results relating to amlitelimab which “confirm its potential as the…
Sanofi announces phase II results for Amlitelimab – 03/11/2024 at 07:08
Sanofi SA SASY.PA: * NEW PHASE II RESULTS RELATING TO AMLITELIMAB CONFIRM ITS POTENTIAL AS BEST-IN-CLASS DRUG IN TERMS OF MAINTAINING RESPONSE IN THE TREATMENT OF ATOPIC DERMATITIS *BREAKING DATA…
Sanofi: positive results against chronic urticaria
(AOF) – Phase II results show that rilzabrutinib can quickly reduce the severity of itching caused by chronic spontaneous urticaria and significantly improve disease activity in adults. This is what…
Sanofi: positive phase II data in urticaria – 02/26/2024 at 07:08
(CercleFinance.com) – Sanofi announces the results of the RILECSU phase II study showing that its rilzabrutinib can quickly reduce the severity of itching caused by chronic spontaneous urticaria and significantly…
Sanofi: Positive phase II data in urticaria
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Sanofi: positive phase II data in urticaria
(CercleFinance.com) – Sanofi announces the results of the RILECSU phase II study showing that its rilzabrutinib can quickly reduce the severity of itching caused by chronic spontaneous urticaria and significantly…
Sanofi Presents Phase II Results of Rilzabrutinib at AAAAI Congress
By Alexandra Saintpierre Published on 02/25/2024 at 6:18 p.m. Photo credit © Sanofi (Boursier.com) — Breaking data presented…
Sanofi: FDA grants priority review to Dupixent for COPD – 02/23/2024 at 09:41
(AOF) – Sanofi announces that the FDA grants priority review to the biologics license application for Dupixent for the treatment of chronic obstructive pulmonary disease (COPD) with type 2 inflammation.…